Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells

Oncology Letters

Volumn 5, Issue 6, 2013, Pages 1826-1832

  Zhang, Lin ^a   Hou, Yanhong ^a   Zhang, Jian ^b   Hu, Jing ^a   Zhang, Kunpeng ^a  

^a 309TH HOSPITAL OF PLA   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bispecific antibody; Cytokine induced killer cell; Gastric cancer; Immunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NORMAL HUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR GROWTH;

EID: 84876491390     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1281     Document Type: Article

References (36)

1. Parkin DM, Poisani P and Ferlay: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999.
2. Stein HJ, Sendler A, Fink U and Siewert JR: Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 80: 659-682, 2000.
3. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153: 1687-1696, 1994.
4. Schmidt-Wolf IG, Lefterova P and Mehta BA, et al: Phenotypic characterization and identification of effectors cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21: 1673-1679, 1993.
5. Märten A, Ziske C, Schöttker B, et al: Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 24: 502-510, 2001.
6. Hui D, Qiang L, Jian W, et al: A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immuno-therapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 41: 36-41, 2009.
7. Li H, Wang C, Yu J, et al: Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11: 1076-1083, 2009.
8. Beun GD, van de Welde CJ and Fleuren GJ: T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition? Immunol Today 15: 11-15, 1994.
9. Fury MG, Lipton A, Smith KM, Winston CB and Pfster DG: A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother 57: 155-163, 2008.
10. + malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 33: 452-459, 2005.
11. Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P and Lindhofer H: Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 3 anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 123: 1181-1189, 2008.
12. Wimberger P, Xiang W, Mayr D, Diebold J, Dreier T, Baeuerle PA and Kimmig R: Efficient tumor cell lysis by autologous, tumor-resident T-lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. Int J Cancer 105: 241-248, 2003.
13. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P and Slavin S: Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 36: 997-1003, 2008.
14. + tumors. J Hematother Stem Cell Res 10: 247-260, 2001.
15. Tita-Nwa F, Moldenhauer G, Herbst M, Kleist C, Ho AD and Kornacker M: Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol Immunother 56: 1911-1920, 2 0 07.
16. Hoyle C, Bangs CD, Chang P, et al: Expansion of Philadelphia chromosome-negative CD3(+) CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92: 3318 -3312 7, 1998.
17. Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG and Negrin RS: Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12: 1859-1867, 2006.
18. + killer cells. Blood 86: 3493-3499, 1995.
19. + killer cells. Ann Hematol 74: 51-56, 1997.
20. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG and Negrin RS: Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 87: 453-458, 1994.
21. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AM, Goey SH, Gratama JW, Lamers CH, et al: Regression of advanced ovarian carcinoma by intraperitoneal treatment w it h a utologous T ly mphocy tesretargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87: 1463-1469, 1995.
22. de Gast GC, Haagen IA, van Houten AA, Klein SC, Duits AJ, de Weger RA, Vroom TM, Clark MR, Phillips J and van Dijk AJ: CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40: 390-396, 1995.
23. Kroesen BJ, Bakker A, van Lier RA, et al: Bispecific antibody-2011;mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res 55: 4409-4415, 1995.
24. Marmé A, Strauss G, Bastert G, Grischke EM and Moldenhauer G: Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 101: 183-189, 2002.
25. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
26. Fakih MG, Wilding G and Lombardo J: Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6: 152-156, 2006.
27. Katzenwadel A, Schleer H, Gierschner D, Wetterauer U and Elsässer-Beile U. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res 20: 1551-1555, 2000.
28. de Leij L, Molema G, Helfrich W and Kroesen BJ: Bispecific antibodies for treatment of cancer in experimental animal models and man. Adv Drug Deliv Rev 31: 105-129, 1998.
29. Verneris MR, Arshi A, Edinger M, Kornacker M, Natkunam Y, Karami M, Cao YA, Marina N, Contag CH and Negrin RS. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res 11: 4561-4570, 2005.
30. Scambia G, Benedetti Panici P, Ferrandina G, et al: Significance of epidermal growth factor receptor expression in primary human endometrial cancer. Int J Cancer 56: 26-30, 1994.
31. Mukohara T, Kudoh S, Yamauchi S, et al: Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41: 123-130, 2003.
32. Xie FH and Wang RX: The research progress of the relationship between the way of EGFR family's signal transfer and breast cancer. Int J Lab Med 27: 1004-1008, 2006.
33. Kameda T, Yasui W, Tsujino T, et al: Tyrosine kinase activity of epidermal growth factor receptor in human gastric carcinomas. Pathol Res Pract 188: 37-43, 1992.
34. Yasui W, Hata T, Yokozaki H, et al: Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer 41: 211-217, 1998.
35. Pinto C, Difabio F, Siena S, et al: Phase - study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18: 510-517, 2007.
36. Han SW, Oh DY, Im SA, et al: Phase - study and biomarker analysis of cetuximab combined with modifed FOLFOX6 in advanced gastric cancer. Br J Cancer 100: 298-304, 2009.